- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Cognition Therapeutics GAAP EPS of -$0.05 beats by $0.02 | 5 | Seeking Alpha | ||
| 07.05. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update | 534 | GlobeNewswire (Europe) | Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to informregistrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics... ► Artikel lesen | |
| 07.05. | COGNITION THERAPEUTICS INC - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Cognition Therapeutics plant entscheidende Studie für Demenz-Wirkstoff | 2 | Investing.com Deutsch | ||
| 31.03. | Cognition Therapeutics plans late-stage trial for dementia drug | 1 | Investing.com | ||
| COGNITION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 31.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics CEO Issues Letter to Shareholders | 281 | GlobeNewswire (Europe) | Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE... ► Artikel lesen | |
| 26.03. | Cognition Therapeutics posts narrower 2025 loss, eyes DLB trial | 4 | Investing.com | ||
| 26.03. | COGNITION THERAPEUTICS INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 26.03. | Cognition Therapeutics: Verlust reduziert, Fokus auf Studie zu Lewy-Körper-Demenz | 1 | Investing.com Deutsch | ||
| 26.03. | COGNITION THERAPEUTICS INC - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 26.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update | 616 | GlobeNewswire (Europe) | -Advancing zervimesine clinical development in DLB psychosis - - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y.,... ► Artikel lesen | |
| 26.03. | Cognition Therapeutics GAAP EPS of -$0.32 beats by $0.07 | 1 | Seeking Alpha | ||
| 23.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results | 1 | GlobeNewswire (USA) | ||
| 17.03. | Cognition Therapeutics präsentiert positive Studiendaten zum Demenz-Wirkstoff Zervimesine | 1 | Investing.com Deutsch | ||
| 17.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 | 2 | GlobeNewswire (USA) | ||
| 02.03. | Cognition Therapeutics shifts focus to DLB psychosis treatment | 1 | Investing.com | ||
| 02.03. | Cognition Therapeutics, Inc.: Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis | 296 | GlobeNewswire (Europe) | PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders... ► Artikel lesen | |
| 02.03. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,95 | -1,07 % | Curevac-Gründer wirft Biontech Täuschung vor | TÜBINGEN/MAINZ (dpa-AFX) - Nach der Übernahme des Biotechunternehmens Curevac durch Biontech wirft Curevac-Gründer Ingmar Hoerr dem Konkurrenten Täuschung vor. Hintergrund sind die Schließungspläne... ► Artikel lesen | |
| AMGEN | 287,20 | +0,26 % | Maria Elvira Salazar trades in Amgen, Carrier Global, and Microsoft stocks | ||
| NOVAVAX | 7,840 | -4,39 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| BIOGEN | 175,02 | +3,03 % | Eisai, Biogen Say FDA Extends Review Of LEQEMBI IQLIK As A Starting Dose For Early AD | WESTON (dpa-AFX) - Eisai Co. Ltd (ESALY.PK) and Biogen Inc. (BIIB) on Friday said the U.S. Food and Drug Administration has extended by three months the review of LEQEMBI IQLIK as a starting... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,950 | +0,94 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 12,360 | +3,69 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates | Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027Recently resumed patient screening in MAGNITUDE... ► Artikel lesen | |
| TEMPUS AI | 39,120 | -2,18 % | Tempus AI nach erneutem Kursrückgang: Risiko-Chance-Profil spitzt sich nach Q1-Zahlen weiter zu | Tempus AI hat nach den Q1-Zahlen erneut einen Kursrückgang verzeichnet, der nach Einschätzung eines Beitrags auf Seeking Alpha ein attraktives Chance-Risiko-Profil für risikobereite Anleger eröffnen... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,242 | +9,89 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,450 | +0,91 % | BioMarin stock price target raised to $110 by Freedom Broker | ||
| SAREPTA THERAPEUTICS | 16,100 | -1,23 % | Sarepta tumbles as its gene therapy sales decline further | ||
| EXELIXIS | 43,500 | +3,22 % | TD Cowen Sees Pipeline Growth Opportunities Supporting Exelixis, Inc. (EXEL) Outlook | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,110 | +1,42 % | PacBio: HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss | ||
| CARDIOL THERAPEUTICS | 1,172 | +1,38 % | Cardiol Therapeutics Inc: Cardiol to publish phase II Maveric results in JAHA | ||
| VAXART | 0,380 | 0,00 % | Vaxart anticipates early 2027 primary efficacy readout while aiming for Q2 sentinel data release | ||
| ARBUTUS BIOPHARMA | 3,650 | -1,08 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen |
COGNITION THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,210 Euro und damit +2,54 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COGNITION THERAPEUTICS INC finden Sie auf Wallstreet Online.